NO20043215L - Nye alkansulfonamider som endothelin-antagonister - Google Patents

Nye alkansulfonamider som endothelin-antagonister

Info

Publication number: NO20043215L
Authority: NO; Norway
Prior art keywords: alkanesulfonamides; novel; endothelin antagonists; endothelin; antagonists
Prior art date: 2002-01-02

Application number

NO20043215A

Other languages

English (en)

Other versions

NO327220B1 (no

Inventor

Martin Bolli

Thomas Weller

Walter Fischli

Martine Clozel

Christophe Boss

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-02

Filing date

2004-07-29

Publication date

2004-07-29

2004-07-29 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2004-07-29 Publication of NO20043215L publication Critical patent/NO20043215L/no

2009-05-18 Publication of NO327220B1 publication Critical patent/NO327220B1/no

Links

102000002045 Endothelin Human genes 0.000 title 1
108050009340 Endothelin Proteins 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Gynecology & Obstetrics (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20043215A 2002-01-02 2004-07-29 Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser NO327220B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP0200002		2002-01-02
PCT/EP2002/013970 WO2003055863A1 (en)	2002-01-02	2002-12-10	Novel alkansulfonamides as endothelin antagonists

Publications (2)

Publication Number	Publication Date
NO20043215L true NO20043215L (no)	2004-07-29
NO327220B1 NO327220B1 (no)	2009-05-18

Family

ID=8164767

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043215A NO327220B1 (no)	2002-01-02	2004-07-29	Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser

Country Status (20)

Country	Link
US (1)	US7323465B2 (no)
JP (1)	JP4769418B2 (no)
KR (1)	KR100940432B1 (no)
CN (1)	CN100537546C (no)
AR (1)	AR037943A1 (no)
AT (1)	ATE381545T1 (no)
AU (1)	AU2002361033B8 (no)
BR (1)	BR0215424A (no)
CA (1)	CA2471220C (no)
DE (1)	DE60224223T2 (no)
ES (1)	ES2297040T3 (no)
HU (1)	HUP0500082A2 (no)
IL (2)	IL162534A0 (no)
MX (1)	MXPA04006457A (no)
MY (1)	MY138502A (no)
NO (1)	NO327220B1 (no)
NZ (1)	NZ533693A (no)
TW (1)	TWI248436B (no)
WO (1)	WO2003055863A1 (no)
ZA (1)	ZA200404927B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008120093A1 (en) *	2007-04-03	2008-10-09	Pfizer Inc.	Sulfonamides and pharmaceutical compositions thereof
IT1393136B1 (it) *	2009-03-11	2012-04-11	Sifa Vitor S R L	Procedimento per la preparazione del bosentan
US20100256371A1 (en) *	2009-04-02	2010-10-07	Glenmark	Processes for the preparation of bosentan and its intermediates thereof
AR077999A1 (es) *	2009-09-02	2011-10-05	Vifor Int Ag	Antagonistas de pirimidin y triazin-hepcidina
EP2907811A1 (en) *	2014-02-14	2015-08-19	Actelion Pharmaceuticals Ltd.	Process for manufacturing pyrimidine sulfamide derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5739333A (en)	1995-05-16	1998-04-14	Tanabe Seiyaku Co., Ltd.	Sulfonamide derivative and process for preparing the same
JP3013752B2 (ja) *	1995-05-16	2000-02-28	田辺製薬株式会社	スルホンアミド誘導体
KR100456650B1 (ko) *	1995-12-20	2005-06-20	야마노우치세이야쿠 가부시키가이샤	아릴에텐설폰아미드유도체
WO1998003488A1 (en) *	1996-07-23	1998-01-29	Shionogi & Co., Ltd.	Novel pyrimidine compounds and drug compositions
JP3116347B2 (ja) *	1996-11-13	2000-12-11	田辺製薬株式会社	医薬組成物
WO1998057938A1 (en) *	1997-06-19	1998-12-23	Yamanouchi Pharmaceutical Co., Ltd.	Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same
CN100424079C (zh) *	1999-09-03	2008-10-08	埃科特莱茵药品有限公司	双磺胺
GB0023074D0 (en) *	2000-09-20	2000-11-01	Pfizer Ltd	Pyridazines

2002
- 2002-12-10 WO PCT/EP2002/013970 patent/WO2003055863A1/en not_active Ceased
- 2002-12-10 AT AT02795133T patent/ATE381545T1/de active
- 2002-12-10 BR BR0215424-2A patent/BR0215424A/pt not_active IP Right Cessation
- 2002-12-10 NZ NZ533693A patent/NZ533693A/en not_active IP Right Cessation
- 2002-12-10 CN CNB028266447A patent/CN100537546C/zh not_active Expired - Fee Related
- 2002-12-10 MX MXPA04006457A patent/MXPA04006457A/es active IP Right Grant
- 2002-12-10 DE DE60224223T patent/DE60224223T2/de not_active Expired - Lifetime
- 2002-12-10 ES ES02795133T patent/ES2297040T3/es not_active Expired - Lifetime
- 2002-12-10 KR KR1020047010218A patent/KR100940432B1/ko not_active Expired - Fee Related
- 2002-12-10 AU AU2002361033A patent/AU2002361033B8/en not_active Ceased
- 2002-12-10 US US10/500,485 patent/US7323465B2/en not_active Expired - Fee Related
- 2002-12-10 JP JP2003556394A patent/JP4769418B2/ja not_active Expired - Fee Related
- 2002-12-10 HU HU0500082A patent/HUP0500082A2/hu unknown
- 2002-12-10 IL IL16253402A patent/IL162534A0/xx unknown
- 2002-12-10 CA CA2471220A patent/CA2471220C/en not_active Expired - Fee Related
- 2002-12-19 AR ARP020105030A patent/AR037943A1/es active IP Right Grant
- 2002-12-26 TW TW091137487A patent/TWI248436B/zh not_active IP Right Cessation
- 2002-12-30 MY MYPI20024923A patent/MY138502A/en unknown
2004
- 2004-06-15 IL IL162534A patent/IL162534A/en not_active IP Right Cessation
- 2004-06-22 ZA ZA2004/04927A patent/ZA200404927B/en unknown
- 2004-07-29 NO NO20043215A patent/NO327220B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2297040T3 (es)	2008-05-01
AU2002361033A1 (en)	2003-07-15
TWI248436B (en)	2006-02-01
DE60224223T2 (de)	2008-12-04
US7323465B2 (en)	2008-01-29
MY138502A (en)	2009-06-30
CA2471220C (en)	2010-11-16
AU2002361033B2 (en)	2008-11-20
MXPA04006457A (es)	2004-10-04
US20050085639A1 (en)	2005-04-21
NZ533693A (en)	2007-02-23
NO327220B1 (no)	2009-05-18
IL162534A0 (en)	2005-11-20
KR20040073525A (ko)	2004-08-19
IL162534A (en)	2011-07-31
AU2002361033B8 (en)	2009-01-29
JP4769418B2 (ja)	2011-09-07
TW200404063A (en)	2004-03-16
CN100537546C (zh)	2009-09-09
AR037943A1 (es)	2004-12-22
ATE381545T1 (de)	2008-01-15
CN1612864A (zh)	2005-05-04
WO2003055863A1 (en)	2003-07-10
JP2005513155A (ja)	2005-05-12
KR100940432B1 (ko)	2010-02-10
DE60224223D1 (de)	2008-01-31
BR0215424A (pt)	2004-12-14
HUP0500082A2 (hu)	2005-04-28
CA2471220A1 (en)	2003-07-10
ZA200404927B (en)	2005-11-30

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
DK1523493T3 (da)	2013-12-02	Nye tubulysinanaloge
NO20044588L (no)	2004-10-25	Nye forbindelser
NO20055219D0 (no)	2005-11-04	Nye forbindelser
NO20035848L (no)	2004-02-27	Nye vevsfaktorrettede antistoffer som antikoagulanter
PL373336A1 (pl)	2005-08-22	Pirazolopirydyny podstawione karbaminianem
NO20054224D0 (no)	2005-09-12	Nye 2-pyridinkarboksamidderivater
NO20052739D0 (no)	2005-06-07	CCR5-antagonister som medikamenter
IS8006A (is)	2005-08-29	Setin pýrimidínón
NO20054005D0 (no)	2005-08-29	Nye arylpiperazinylforbindelser
AU2003259267A1 (en)	2004-02-25	Substituted aminopyrimidines as neurokinin antagonists
NO20052928D0 (no)	2005-06-15	Nye kjemiske forbindelser
NO20044046L (no)	2004-11-15	Substituerte hydroksyetylaminer
NO20033679L (no)	2003-08-19	Nye pyrimidinforbindelser
DE60302137D1 (de)	2005-12-08	Piperidinderivate
DK1704148T3 (da)	2011-06-14	Nye kondenserede pyrrolocarbazoler
NO20034695D0 (no)	2003-10-20	Nye sammensetninger
DK1492934T3 (da)	2010-10-04	Dørenhed
DK1648882T3 (da)	2008-11-24	3-fluor-piperidiner som NMDA/NR2B-antagonister
NO20040563L (no)	2004-03-08	Nye benzokondenserte heterocykler som endotelin antagonister.
ATE496887T1 (de)	2011-02-15	Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
DK1499622T3 (da)	2009-06-08	Meterotricyclyl-6-alkylidenpenemer som beta-lactamaseinhibitorer
NO20026285D0 (no)	2002-12-30	Nye peptider
NO20044867L (no)	2004-12-23	Nye salter
NO20044098L (no)	2004-10-04	Nye forbindelser
NO20053598D0 (no)	2005-07-22	Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.